CD266 (FN14)-PE-Vio770, human and mouse，130-123-405，美天旎

Clone REA1216 recognizes CD266, also known as FN14, tumor necrosis factor receptor superfamily member 12A (TNFRSF12A), or tweak-receptor (TWEAKR). CD266 is a 14 kDa type I transmembrane glycoprotein belonging to the tumor necrosis factor (TNF) receptor superfamily and binds to TWEAK, a proinflammatory cytokine, as its only known ligand. The cytoplasmic tail of CD266 contains a TRAF binding motif and binds to TRAF1, TRAF2, TRAF3, and TRAF5. Both TWEAK dependent and independent CD266 signaling lead to activation of the NF-κB pathway. TWEAK independent signaling is shown when CD266 is ectopically overexpressed in vitro. Expression of CD266 is found on a wide variety of cells except for primary T and B cells. Elevated expression is often found in response to several growth factors, cytokines, hormones, after tissue injury, and in solid tumors such as glioblastoma multiforme tumors. Varied functions of TWEAK signaling include promotion of wound healing and regeneration, to influence the transition from innate to adaptive immunity and regulation of cell death and tumor progression.

Additional information: Clone REA1216 displays negligible binding to Fc receptors.

TNFRSF12A, FN14, TWEAKR

Technical specifications